Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06898957 · ClinicalTrials.gov registry record · Phase 1

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

A Phase 1 study of Small-cell Lung Cancer, sponsored by Amgen.

Recruiting
Registry status
Phase 1
Development phase
200
Enrollment target
20
Study locations

NCT06898957 is a Phase 1 study of Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 200 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06898957, a Phase 1 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG Atezolizumab
  • DRUG Durvalumab
  • DRUG Tarlatamab
  • DRUG YL201

Study Locations (20)

Other

  • Fujian Cancer Hospital - Fuzhou
  • Institut Bergonie - Bordeaux
  • Centre Leon Berard - Lyon
  • Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
  • Gustave Roussy - Villejuif
  • Universitaetsklinikum Essen - Essen

Washington

  • Swedish Medical Center - Seattle
  • Fred Hutchinson Cancer Center - Seattle

California

  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine

Connecticut

  • Yale New Haven Hospital - New Haven

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Siteman Cancer Center - St Louis

North Dakota

  • Sanford Roger Maris Cancer Center - Fargo

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-05-16
Est. Completion 2031-04-23
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06898957

The ClinicalTrials.gov registry entry for NCT06898957 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (13% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.

NCT06898957 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Washington, California.

Frequently Asked Questions

What is clinical trial NCT06898957 about?

NCT06898957 is a clinical study titled "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)". The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

What is the current status of trial NCT06898957?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-05-16. Estimated completion is 2031-04-23.

What conditions does trial NCT06898957 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT06898957?

The interventions under investigation include: Atezolizumab (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG), YL201 (DRUG).

Who is sponsoring clinical trial NCT06898957?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06898957 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.